Literature DB >> 7566180

Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin.

P M Takahara1, A C Rosenzweig, C A Frederick, S J Lippard.   

Abstract

The success of cisplatin in cancer chemotherapy derives from its ability to crosslink DNA and alter the structure. Most cisplatin-DNA adducts are intrastrand d(GpG) and d(ApG) crosslinks, which unwind and bend the duplex to facilitate the binding of proteins that contain one or more high-mobility group (HMG) domains. When HMG-domain proteins such as HMG1, IXR (intrastrand-crosslink recognition) protein from yeast, or human upstream-binding factor (hUBF) bind cisplatin intrastrand crosslinks, they can be diverted from their natural binding sites on the genome and shield the adducts from excision repair. These activities sensitize cells to cisplatin and contribute to its cytotoxic properties. Crystallographic information about the structure of cisplatin-DNA adducts has been limited to short single-stranded deoxyoligonucleotides such as cis-[Pt(NH3)2(d(pGpG))]. Here we describe the X-ray structure at 2.6 A resolution of a double-stranded DNA dodecamer containing this adduct. Our information provides, to our knowledge, the first crystallographic look at a platinated DNA duplex and should help the design of new platinum and other metal crosslinking antitumour drug candidates. Moreover, the structure reveals a unique fusion of A- and B-type DNA segments that could be of more general importance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7566180     DOI: 10.1038/377649a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  129 in total

1.  Solution structure of biopolymers: a new method of constructing a bead model.

Authors:  E Banachowicz; J Gapiński; A Patkowski
Journal:  Biophys J       Date:  2000-01       Impact factor: 4.033

2.  Intrinsic conformational energetics associated with the glycosyl torsion in DNA: a quantum mechanical study.

Authors:  Nicolas Foloppe; Brigitte Hartmann; Lennart Nilsson; Alexander D MacKerell
Journal:  Biophys J       Date:  2002-03       Impact factor: 4.033

3.  A crystallographic map of the transition from B-DNA to A-DNA.

Authors:  J M Vargason; K Henderson; P S Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

4.  Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines.

Authors:  T A Dunn; H J Schmoll; V Grünwald; C Bokemeyer; J Casper
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

5.  Double-check probing of DNA bending and unwinding by XPA-RPA: an architectural function in DNA repair.

Authors:  M Missura; T Buterin; R Hindges; U Hübscher; J Kaspárková; V Brabec; H Naegeli
Journal:  EMBO J       Date:  2001-07-02       Impact factor: 11.598

6.  Sequence-dependent dynamics of duplex DNA: the applicability of a dinucleotide model.

Authors:  T M Okonogi; S C Alley; A W Reese; P B Hopkins; B H Robinson
Journal:  Biophys J       Date:  2002-12       Impact factor: 4.033

7.  MutS inhibits RecA-mediated strand exchange with platinated DNA substrates.

Authors:  Melissa A Calmann; M G Marinus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-16       Impact factor: 11.205

8.  Enhancement of DNA flexibility in vitro and in vivo by HMGB box A proteins carrying box B residues.

Authors:  Nadia T Sebastian; Emily M Bystry; Nicole A Becker; L James Maher
Journal:  Biochemistry       Date:  2009-03-17       Impact factor: 3.162

9.  Bifunctional cross-linking approaches for mass spectrometry-based investigation of nucleic acids and protein-nucleic acid assemblies.

Authors:  M Scalabrin; S M Dixit; M M Makshood; C E Krzemien; Daniele Fabris
Journal:  Methods       Date:  2018-05-10       Impact factor: 3.608

10.  Synthesis and anti-cancer activities of a water soluble gold(III) porphyrin.

Authors:  Aaron D Lammer; Melissa E Cook; Jonathan L Sessler
Journal:  J Porphyr Phthalocyanines       Date:  2015-01       Impact factor: 1.811

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.